Australian clinical-stage pharmaceutical company ENA Respiratory has been awarded an additional $3.8 million contract from the US Department of Defense (DOD) to support ongoing research and development of INNA-051, a first-in-class, intranasal, innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations.   The new funding adds to the $4.38 […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!